GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (NAS:NERV) » Definitions » Cyclically Adjusted PB Ratio

Minerva Neurosciences (Minerva Neurosciences) Cyclically Adjusted PB Ratio : 0.15 (As of May. 24, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Minerva Neurosciences Cyclically Adjusted PB Ratio?

As of today (2024-05-24), Minerva Neurosciences's current share price is $2.45. Minerva Neurosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $16.22. Minerva Neurosciences's Cyclically Adjusted PB Ratio for today is 0.15.

The historical rank and industry rank for Minerva Neurosciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

NERV' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.73
Current: 0.15

During the past years, Minerva Neurosciences's highest Cyclically Adjusted PB Ratio was 0.73. The lowest was 0.00. And the median was 0.00.

NERV's Cyclically Adjusted PB Ratio is ranked better than
84.66% of 652 companies
in the Biotechnology industry
Industry Median: 1.74 vs NERV: 0.15

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Minerva Neurosciences's adjusted book value per share data for the three months ended in Mar. 2024 was $-5.232. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $16.22 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Minerva Neurosciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Minerva Neurosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Neurosciences Cyclically Adjusted PB Ratio Chart

Minerva Neurosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.09 0.37

Minerva Neurosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.53 0.41 0.37 0.16

Competitive Comparison of Minerva Neurosciences's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Minerva Neurosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Neurosciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's Cyclically Adjusted PB Ratio falls into.



Minerva Neurosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Minerva Neurosciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.45/16.22
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Neurosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Minerva Neurosciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-5.232/131.7762*131.7762
=-5.232

Current CPI (Mar. 2024) = 131.7762.

Minerva Neurosciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 12.795 100.560 16.767
201409 24.606 100.428 32.287
201412 22.343 99.070 29.719
201503 24.088 99.621 31.863
201506 22.128 100.684 28.961
201509 20.409 100.392 26.789
201512 17.902 99.792 23.640
201603 19.082 100.470 25.028
201606 27.721 101.688 35.923
201609 26.003 101.861 33.640
201612 24.208 101.863 31.317
201703 23.166 102.862 29.678
201706 22.392 103.349 28.551
201709 26.910 104.136 34.053
201712 27.169 104.011 34.422
201803 25.042 105.290 31.342
201806 22.847 106.317 28.318
201809 20.881 106.507 25.835
201812 18.545 105.998 23.055
201903 15.871 107.251 19.500
201906 13.790 108.070 16.815
201909 11.383 108.329 13.847
201912 5.686 108.420 6.911
202003 3.799 108.902 4.597
202006 11.208 108.767 13.579
202009 10.877 109.815 13.052
202012 9.862 109.897 11.825
202103 8.497 111.754 10.019
202106 6.773 114.631 7.786
202109 5.258 115.734 5.987
202112 1.494 117.630 1.674
202203 -0.138 121.301 -0.150
202206 -1.570 125.017 -1.655
202209 -2.668 125.227 -2.808
202212 -3.750 125.222 -3.946
202303 -4.984 127.348 -5.157
202306 -1.789 128.729 -1.831
202309 -2.866 129.860 -2.908
202312 -4.069 129.419 -4.143
202403 -5.232 131.776 -5.232

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Minerva Neurosciences  (NAS:NERV) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Minerva Neurosciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Minerva Neurosciences (Minerva Neurosciences) Business Description

Traded in Other Exchanges
Address
1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Executives
Ag Boehringer 10 percent owner BINGER STRABE 173, INGELHEIM AM RHEIN 2M 55216
Boehringer Ingelheim International Gmbh 10 percent owner 200 PARK AVENUE, C/O KLAUS H JANDER ESQ ROGERS & WELLS LL, NEW YORK NY 10166
Remy Luthringer officer: EVP and Head of R&D C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Geoff Race officer: EVP and CFO C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Frederick W Ahlholm officer: Chief Accounting Officer C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Kupfer director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Joseph H. Reilly officer: Chief Business Officer C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Van Heek G Jan director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Richard E. Russell officer: President C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
William F Doyle director
Hans Peter Hasler director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Index Venture Associates Iii Ltd 10 percent owner 5TH FLOOR, 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE1 3FG
Index Venture Associates Iv Ltd 10 percent owner 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE4 9WG

Minerva Neurosciences (Minerva Neurosciences) Headlines

From GuruFocus